Notably, IFT20 clusters with TCRs at the immune synapse and associates with the ζ- and ɛ-chains of CD3 in response to TCR engagement. TCR–CD3 complex assembly is initiated in the endoplasmic ...

that consists of a soluble TCR targeting gp100 expressed on cancer cells fused to a protein that binds CD3 receptors on lymphocytes – as a treatment for unresectable or metastatic uveal melanoma.

The partnership leverages the sensitive, specific and safe (3S) TCR characterisation and generation capabilities of Medigene and EpimAb's cluster of differentiation 3 (CD3) antibody and TCR-Fab in ...

The multi-target collaboration combines the respective expertise of each company with Medigene’s 3S (sensitive, specific and safe) TCR generation and characterization capabilities and EpimAb’s ...

To enable this innovation, Medigene combined TCR-guided precision targeting with innate NK cell killing. The Company has developed a proprietary universal scaffold that allows its 3S TCRs to function ...

TCR generation and characterization capabilities and EpimAb’s proprietary CD3 antibody and T-FIT (TCR-Fab in tandem) platform. The resultant bispecific therapeutics are expected to provide ...

These optimal 3S TCRs can subsequently be merged with a Cluster of Differentiation 3 (CD3) T cell engaging antibody. The TCR-TCEs specifically redirect the patient’s own T cells towards the ...

Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, today ann ...